Anti-BTLA/CD272 Antibody (Tifcemalimab)
Catalog No.
F1387
Anti-BTLA/CD272 Antibody (Tifcemalimab)
Featured Products
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuator) monoclonal antibody. Tifcemalimab binds to BTLA, blocking the HVEM-BTLA interaction and thus blocking the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in cancer research.
146 kDa
Dry ice
2236068-83-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
TAB-004, JS-004
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q7Z6A9
Human
Unconjugated
Monoclonal
IgG4
ELISA, FACS, Kinetics, Functional assay, Animal Model
BTLA / CD272
Please avoid freeze-thaw cycles.